Afecta Pharmaceuticals, Inc. is a patient-centric, physician driven pharmaceutical company focused on discovering and optimizing small molecules to treat inflammatory diseases. The company has validated its proprietary Artificial Intelligence powered disease/drug targeting platform, PharmetRx™, by discovering and optimizing SPN-810, a drug in development with Supernus Pharmaceuticals (NASDAQ: SUPN). SPN-810 has received FDA Fast Track status and is expected to enter the market in 2019 and reach $1B in revenues at peak. Afecta has now developed a new pipeline of de-risked, small molecule immune- modulating drugs with fast-to-market potential through the FDA 505(b)(2) pathway. Our current internal drug development programs focus on addressing unmet needs in dermatology using several of the drugs we have discovered